Fundraising Fox
/Companies
Sign in

Glyscend

Baltimore, US · Delaware corporation · 3 known investors

Find your way into Glyscend

Sign up to find every way you can get introduced to Glyscend

  • Your email: who you already know at Glyscend, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Glyscend team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity. Its approach originated from research on how certain bariatric surgeries improve glucose and metabolic regulation and produce sustained weight loss.

BiotechDeep TechDigital HealthHealthtechLongevity

Founders & leadership

AN
Ashish NimgaonkarFounder
DMDennis McWilliams
Dennis McWilliamsNamed on SEC filingManaging Director at Sante Ventures
CC
Casey CunninghamNamed on SEC filing
LR
Leighton ReadNamed on SEC filing
BSBob Soh
Bob SohNamed on SEC filing

Investors · 3

Brandon Capital PartnersreportedMelbourne

How we know: funding news · press coverage · Not right? Tell us

Breakout Labsreported

How we know: press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$4.8M disclosed across 1 round · 2020

▶$4.8MraisedFeb 2020 · 10 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Dennis McWilliamsDirector
  • Casey CunninghamDirector
  • Ashish NimgaonkarExecutive Officer, Director
  • Leighton ReadDirector
  • Bob SohDirector
Offering amount
$20.9M
Amount sold
$4.8M
Minimum investment
$1
First sale
Feb 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Novo NordiskNovo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies. It serves patients and healthcare markets globally.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies working in the same space as Glyscend.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase II2017$500K
National Science FoundationPhase ISTTR2015$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Glyscend do?
Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity. Its approach originated from research on how certain bariatric surgeries improve glucose and metabolic regulation and produce sustained weight loss.
Who founded Glyscend?
Glyscend was founded by Ashish Nimgaonkar.
Who are Glyscend's investors?
Glyscend's investors include Brandon BioCatalyst, Brandon Capital Partners, Breakout Labs.
How much funding has Glyscend raised?
Glyscend has disclosed $4.8M raised across 1 round.
Where is Glyscend headquartered?
Glyscend is headquartered in Baltimore, US.